<DOC>
	<DOCNO>NCT00931528</DOCNO>
	<brief_summary>RATIONALE : Tadalafil may help prevent erectile dysfunction patient prostate cancer treat radiation therapy . It yet know whether tadalafil effective placebo prevent erectile dysfunction . PURPOSE : This randomized phase III trial study tadalafil see well work compare placebo prevent erectile dysfunction patient prostate cancer treat radiation therapy .</brief_summary>
	<brief_title>Tadalafil Preventing Erectile Dysfunction Patients With Prostate Cancer Treated With Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether tadalafil maintains spontaneous ( off-drug ) erectile function , measure International Index Erectile Function ( IIEF ) compare placebo week 28-30 initiation radiotherapy patient prostate cancer . Secondary - Determine difference spontaneous ( off-drug ) erectile function tadalafil placebo 1 2 year . - Determine difference overall sexual function measure IIEF tadalafil placebo week 28-30 1 2 year . - Determine difference patient partner overall sexual satisfaction measure Sexual Adjustment Questionnaire ( SAQ ) tadalafil placebo week 28-30 1 2 year . - Determine difference patient partner marital adjustment measure Locke 's Marital Adjustment Test ( LMAT ) tadalafil placebo week 28-30 1 2 year . - Determine association patient partner overall sexual satisfaction measure SAQ patient partner marital adjustment measure LMAT week 28-30 1 2 year . - Determine patient-related factor ( i.e. , age , pretreatment sexual response , tobacco use , comorbidities ) may predict response tadalafil therapy week 28-30 1 2 year . - Determine difference adverse event tadalafil placebo assess Common Toxicity Criteria Adverse Effects ( CTCAE ) v3.0 criterion . Tertiary - Characterization preference erectile function among patient choose stay ( placebo , start ) tadalafil , phosphodiesterase type 5 ( PDE5 ) inhibitor tadalafil , non-PDE5-inhibitor erectile aide , PDE5 inhibitor erectile aide 28-30 week 1 2 year . - Identification radiotherapy factor ( i.e. , modality , prescribe total dose , plan target volume margin , penile bulb dose-volume parameter ) associate erectile function . - Evaluation number patient screened eligibility , number eligible present study , number refuse , number accrue . OUTLINE : This multicenter study . Patients stratify accord age ( ≤ 65 year vs &gt; 65 year ) radiotherapy treatment ( external beam radiation therapy v brachytherapy* ) . Patients randomize 1 2 treatment arm . Note : * Radiotherapy start date brachytherapy patient date procedure . All patient undergo either external beam radiotherapy alone prostate ± seminal vesicle low-dose rate permanent brachytherapy alone . - Arm I : Beginning ≤ 7 day start radiotherapy , patient receive oral tadalafil daily 24 week absence disease progression unacceptable toxicity . - Arm II : Beginning ≤ 7 day start radiotherapy , patient receive oral placebo daily 24 week absence disease progression unacceptable toxicity . Patients complete International Index Erectile Function ( IIEF ) , Sexual Adjustment Questionnaire ( SAQ ) , Locke 's Marital Adjustment Test ( LMAT ) ( applicable ) , Expanded Prostate Cancer Index Composite Sexual Medications Devices Evaluations Supplement questionnaires periodically . Partners spouses complete SAQ-Partner , LMAT ( applicable ) , IIEF questionnaires periodically . After completion study treatment , patient follow 28-30 week , annually 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Diagnosis adenocarcinoma prostate within past 6 month Clinical stage T1bT2b No distant metastasis Clinically negative lymph node establish image ( pelvic ± abdominal CT MRI ) , nodal sampling , dissection within past 3 month Patients lymph node equivocal questionable image eligible provide node ≤ 1.5 cm Lymph node assessment optional investigator 's discretion patient Gleason score &lt; 7 No evidence bone metastases bone scan within past 3 month Equivocal bone scan finding allow provide plain film negative metastasis Bone metastasis assessment optional investigator 's discretion patient Gleason score &lt; 7 Baseline serum prostatespecific antigen ( PSA ) value perform FDAapproved assay within past 3 month meet 1 follow criterion : Gleason score &lt; 7 PSA &lt; 20 ng/mL Gleason score ≥ 7 PSA &lt; 15 ng/mL Planning undergo treatment either external radiotherapy alone prostate ± seminal vesicle dose 7579.2 Gy OR brachytherapy alone Pretreatment erectile function measure International Index Erectile Function questionnaire response 3 , 4 , 5 question 1 Spouse partner patient ( optional ) Male female PATIENT CHARACTERISTICS : Zubrod performance status 01 Serum total testosterone level normal prior initiation radiotherapy No myocardial infarction within past year No heart failure within past 6 month No stroke within past 6 month No uncontrolled arrhythmia , hypotension ( BP &lt; 90/50 mm Hg ) , uncontrolled hypertension ( BP &gt; 170/100 mm Hg ) No know moderate severe renal insufficiency endstage renal disease No known severe hepatic impairment No prior concurrent invasive cancer ( stage &gt; 0 ) except localize basal cell squamous cell skin carcinoma ( stage 0II ) , hematological malignancy ( e.g. , leukemia , lymphoma , myeloma ) unless diseasefree ≥ 5 year No know AIDS base upon current Centers Disease Control ( CDC ) definition No anatomical genital abnormality concurrent condition , estimation physician , would prohibit sexual intercourse prevent study completion No major medical psychiatric illness , opinion investigator , would prevent completion treatment would interfere follow PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior tadalafil allow No prior penile implant history bilateral orchiectomy No prior prostatectomy , prostatic cryosurgery , highintensity focus ultrasound , radionuclide prostate brachytherapy , chemotherapy prostate cancer No prior anticipate combined external radiotherapy brachytherapy No prior anticipate external radiotherapy pelvic ± paraaortic lymph node More 6 month since prior leuteinizing hormonereleasing hormone agonist androgen suppression ( e.g. , leuprolide acetate , goserelin ) , antiandrogen ( e.g. , flutamide , bicalutamide , nilutamide ) , estrogenic ( e.g. , diethylstilbestrol ) agent At least 57 day since prior use mechanical ( vacuum ) device , intracorporeal , intraurethral , topical , oral ( sildenafil , tadalafil , vardenafil ) agent therapy erectile dysfunction ( ED ) supplement enhance sexual function No concurrent medical research study involve treatment ED No concurrent use organic nitrate asneeded nitrate ( e.g. , use nitroglycerin ) No concurrent cimetidine , ketoconazole , itraconazole , erythromycin , ritonavir</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>